EUVIMEDAtrasti EUVIMED
Crossref

Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV‐Related Oropharyngeal Squamous Cell Carcinoma

David S Lee iD, Rajwant S Mahal, Theresa Tharakan iD, Cathryn Collopy, Dorina Kallogjeri, Wade L Thorstad, Douglas R Adkins, Peter Oppelt iD, Jessica Ley iD, Cameron C Wick iD, Jose Zevallos

Otolaryngology–Head and Neck Surgery · 2023

DOI: 10.1002/ohn.182 ↗

At a glance

Journal article in Otolaryngology–Head and Neck Surgery, 2023. Written by David S Lee and 10 co-authors. Institution: Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri, USA. Major MEDLINE topics: Carcinoma, Squamous Cell, Oropharyngeal Neoplasms, Papillomavirus Infections, Ototoxicity. Cited 4 times so far (Crossref); 30 references. Funded by: NIDCD NIH HHS.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Objective

To explore whether deintensification of adjuvant therapy reduces ototoxicity among patients with human papillomavirus (HPV)‐related oropharyngeal squamous cell carcinoma (OPSCC). Study Design Retrospective cohort study.

Setting

Single academic center.

Methods

The ototoxicity rate among adult patients with HPV‐related OPSCC enrolled in the Minimalist Trial (MINT), a prospective phase 2 trial of surgery followed by risk‐adjusted deintensified adjuvant therapy (42 Gy radiation given alone or with a single 100 mg/m 2 dose of cisplatin), was compared to that among a historical cohort treated with standard adjuvant therapy (60‐66 Gy radiation with up to three 100 mg/m 2 doses of cisplatin). Ototoxicity was defined as Common Terminology Criteria for Adverse Events v5.0 ≥ Grade 2. Mixed model analysis was performed to investigate the association between deintensified adjuvant therapy and treatment‐related hearing loss.

Results

A total of 29 patients (58 ears) were analyzed in the MINT cohort, and 27 patients (54 ears) in the historical cohort. The ototoxicity rate was 5% (n = 3/58 ears) in the MINT cohort and 46% (n = 25/54 ears) in the historical cohort (difference, 41%; 95% confidence interval [CI] = 27%‐56%). Patients in the MINT cohort demonstrated a 95% decrease in risk of ototoxicity compared to those in the historical cohort (adjusted odds ratio: 0.05, 95% CI = 0.01‐0.31). Differences in estimated marginal mean threshold shifts were statistically and clinically significant at frequencies ≥ 3 kHz.

Conclusion

The deintensified adjuvant therapy given in MINT led to less ototoxicity than standard adjuvant therapy among patients with HPV‐related OPSCC.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Squamous CellOropharyngeal NeoplasmsPapillomavirus InfectionsOtotoxicityHead and Neck NeoplasmsAdultHumansSquamous Cell Carcinoma of Head and NeckHuman Papillomavirus VirusesCisplatinRetrospective StudiesProspective StudiesHearing

Author keywords

HPV-related oropharyngeal squamous cell carcinomacisplatin ototoxicityhearing outcomesp16+treatment deintensification

Substances

Cisplatin

Authors and institutions

  • Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri, USA.
  • Department of Otolaryngology-Head and Neck Surgery, Division of Adult Audiology, Washington University School of Medicine, St Louis, Missouri, USA.
  • Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri, USA.
  • Department of Medical Oncology, Washington University School of Medicine, St Louis, Missouri, USA.

ORCID profiles: David S Lee, Theresa Tharakan, Peter Oppelt, Jessica Ley, Cameron C Wick

Funding

  • NIDCD NIH HHS

Cite

APA

Lee, D. S., Mahal, R. S., Tharakan, T., Cathryn Collopy, Kallogjeri, D., Thorstad, W. L., Adkins, D. R., Oppelt, P., Ley, J., Wick, C. C., & Zevallos, J. (2023). Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV‐Related Oropharyngeal Squamous Cell Carcinoma. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.182

Vancouver

Lee DS, Mahal RS, Tharakan T, Cathryn Collopy, Kallogjeri D, Thorstad WL, et al. Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV‐Related Oropharyngeal Squamous Cell Carcinoma. Otolaryngology–Head and Neck Surgery. 2023. doi:10.1002/ohn.182

BibTeX
@article{Lee2023,
  author = {Lee, David S and Mahal, Rajwant S and Tharakan, Theresa and Cathryn Collopy and Kallogjeri, Dorina and Thorstad, Wade L and Adkins, Douglas R and Oppelt, Peter and Ley, Jessica and Wick, Cameron C and Zevallos, Jose},
  title = {Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV‐Related Oropharyngeal Squamous Cell Carcinoma},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2023},
  doi = {10.1002/ohn.182}
}
Start for free →